[
  {
    "ts": "2025-11-17T05:00:26+00:00",
    "headline": "Goldman Sachs on brink of best M&A performance in 24 years",
    "summary": "Goldman Sachs is vying to capture its biggest share of the deals market in almost a quarter of a century, with Wall Street’s dominant investment...",
    "url": "https://finance.yahoo.com/news/goldman-sachs-brink-best-m-050026847.html",
    "source": "Financial Times",
    "provider": "yfinance",
    "raw": {
      "id": "4c26c793-7db6-37d7-a0f0-cdd1c5484847",
      "content": {
        "id": "4c26c793-7db6-37d7-a0f0-cdd1c5484847",
        "contentType": "STORY",
        "title": "Goldman Sachs on brink of best M&A performance in 24 years",
        "description": "",
        "summary": "Goldman Sachs is vying to capture its biggest share of the deals market in almost a quarter of a century, with Wall Street’s dominant investment...",
        "pubDate": "2025-11-17T05:00:26Z",
        "displayTime": "2025-11-17T05:00:26Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": null,
        "provider": {
          "displayName": "Financial Times",
          "url": "https://www.ft.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/goldman-sachs-brink-best-m-050026847.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/goldman-sachs-brink-best-m-050026847.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "GS"
            },
            {
              "symbol": "CDTX"
            },
            {
              "symbol": "MRK"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": true,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-11-17T13:00:00+00:00",
    "headline": "Solve Therapeutics Raises $120 Million to Develop Best-in-Class ADCs for Solid Tumors",
    "summary": "SAN DIEGO, November 17, 2025--Solve Therapeutics Raises $120 Million to Develop Best-in-Class ADCs for Solid Tumors",
    "url": "https://finance.yahoo.com/news/solve-therapeutics-raises-120-million-130000156.html",
    "source": "Business Wire",
    "provider": "yfinance",
    "raw": {
      "id": "dee99e2d-5002-3f54-a3a2-8c78517c3416",
      "content": {
        "id": "dee99e2d-5002-3f54-a3a2-8c78517c3416",
        "contentType": "STORY",
        "title": "Solve Therapeutics Raises $120 Million to Develop Best-in-Class ADCs for Solid Tumors",
        "description": "",
        "summary": "SAN DIEGO, November 17, 2025--Solve Therapeutics Raises $120 Million to Develop Best-in-Class ADCs for Solid Tumors",
        "pubDate": "2025-11-17T13:00:00Z",
        "displayTime": "2025-11-17T13:00:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/business-wire.com/a26b902a893bc686adf67a4a642f1e6e",
          "originalWidth": 1024,
          "originalHeight": 512,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/CtdmnO6QyXL7XaE3p_.uYA--~B/aD01MTI7dz0xMDI0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/business-wire.com/a26b902a893bc686adf67a4a642f1e6e.cf.webp",
              "width": 1024,
              "height": 512,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/hHVGq0D0VnazJ1io6C.YCQ--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/a26b902a893bc686adf67a4a642f1e6e.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Business Wire",
          "url": "http://www.businesswire.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/solve-therapeutics-raises-120-million-130000156.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/solve-therapeutics-raises-120-million-130000156.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "MRK"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-11-17T12:31:49+00:00",
    "headline": "Cidara downgraded on Wall Street after Merck agrees to $9.2 billion buyout",
    "summary": "Investing.com -- Cidara Therapeutics was hit with broad downgrades after Merck agreed to buy the company for $221.50 a share in a deal valued at about $9.2 billion.",
    "url": "https://finance.yahoo.com/news/cidara-downgraded-wall-street-merck-123149455.html",
    "source": "Investing.com",
    "provider": "yfinance",
    "raw": {
      "id": "41e728fc-83f1-346f-8201-2da21f85463b",
      "content": {
        "id": "41e728fc-83f1-346f-8201-2da21f85463b",
        "contentType": "STORY",
        "title": "Cidara downgraded on Wall Street after Merck agrees to $9.2 billion buyout",
        "description": "",
        "summary": "Investing.com -- Cidara Therapeutics was hit with broad downgrades after Merck agreed to buy the company for $221.50 a share in a deal valued at about $9.2 billion.",
        "pubDate": "2025-11-17T12:31:49Z",
        "displayTime": "2025-11-17T12:31:49Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": null,
        "provider": {
          "displayName": "Investing.com",
          "url": "https://www.investing.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/cidara-downgraded-wall-street-merck-123149455.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/cidara-downgraded-wall-street-merck-123149455.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "MRK"
            },
            {
              "symbol": "CDTX"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-11-17T08:00:00+00:00",
    "headline": "Solve lines up $120M to push ADCs into further testing",
    "summary": "The startup, which is backed by a dozen investors including Merck & Co., claims its novel “linkers” can help address some of the issues limiting the potential of earlier ADCs.",
    "url": "https://www.biopharmadive.com/news/solve-therapeutics-adc-biotech-startup-financing/805450/",
    "source": "BioPharma Dive",
    "provider": "yfinance",
    "raw": {
      "id": "7d83835b-f1ea-3117-99b9-5fd5c2ccaced",
      "content": {
        "id": "7d83835b-f1ea-3117-99b9-5fd5c2ccaced",
        "contentType": "STORY",
        "title": "Solve lines up $120M to push ADCs into further testing",
        "description": "",
        "summary": "The startup, which is backed by a dozen investors including Merck & Co., claims its novel “linkers” can help address some of the issues limiting the potential of earlier ADCs.",
        "pubDate": "2025-11-17T08:00:00Z",
        "displayTime": "2025-11-17T08:00:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/biopharma_dive_768/7bd263bcae7d0506fb80282303540fe7",
          "originalWidth": 1280,
          "originalHeight": 720,
          "caption": "BioPharma Dive, an Industry Dive publication",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/U3g5.ulK0vcCqcdyFlYvVw--~B/aD03MjA7dz0xMjgwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/biopharma_dive_768/7bd263bcae7d0506fb80282303540fe7.cf.webp",
              "width": 1280,
              "height": 720,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/DH6ljKWVk5FO27mUzvHUcQ--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/biopharma_dive_768/7bd263bcae7d0506fb80282303540fe7.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "BioPharma Dive",
          "url": "https://biopharmadive.com/"
        },
        "canonicalUrl": {
          "url": "https://www.biopharmadive.com/news/solve-therapeutics-adc-biotech-startup-financing/805450/",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/solve-lines-120m-push-adcs-080000879.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "MRK"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]